From the Authors:
We thank Weatherald and colleagues for their supportive comments, and pleasant reminiscence of French cuisine, on our recent report on risk reduction and hemodynamics after initial dual combination of therapies in pulmonary arterial hypertension (1). We fully agree on the importance of pulmonary vascular resistance combined with imaging of the right heart, as there may be dissociation (2), although this is unlikely when pulmonary vascular resistance decreases by more than 50–60% (3). Their other points are also well taken. 1) Redundancies in pulmonary arterial hypertension risk scores easily occur, as most parameters of prognostic relevance are inevitably related to right ventricular function. We could indeed have acknowledged this with greater clarity. 2) Sex differences in risk scores are of great clinical relevance in relation to the greater capacity of the female right ventricle to adapt to increased afterload, as recently reemphasized (4). 3) The inevitable failure of initial dual-combination therapy in high-risk patients strongly argues in favor of their treatment with initial triple-combination therapies.
We like to add that not only initial high-risk patients fail and that the definition of a high-risk status may vary greatly from one score to another. Over half of treated patients actually remain with poor prognosis intermediate or high-risk status whatever the scoring system. This calls for earlier and more intensive combination therapies with parenteral prostanoids and more intensive follow-up with repetitive right heart catheterizations and imaging modalities (5).
Supplementary Material
Footnotes
Originally Published in Press as DOI: 10.1164/rccm.202010-3834LE on October 26, 2020
Author disclosures are available with the text of this letter at www.atsjournals.org.
References
- 1.Badagliacca R, D’Alto M, Ghio S, Argiento P, Bellomo V, Brunetti ND, et al. Risk reduction and hemodynamics with initial combination therapy in pulmonary arterial hypertension. Am J Respir Crit Care Med. doi: 10.1164/rccm.202004-1006OC. [online ahead of print] 28 Aug 2020. [DOI] [PubMed] [Google Scholar]
- 2.van de Veerdonk MC, Kind T, Marcus JT, Mauritz G-J, Heymans MW, Bogaard H-J, et al. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol. 2011;58:2511–2519. doi: 10.1016/j.jacc.2011.06.068. [DOI] [PubMed] [Google Scholar]
- 3.Badagliacca R, Papa S, Manzi G, Miotti C, Luongo F, Sciomer S, et al. Usefulness of adding echocardiography of the right heart to risk-assessment scores in prostanoid-treated pulmonary arterial hypertension. JACC Cardiovasc Imaging. 2020;13:2054–2056. doi: 10.1016/j.jcmg.2020.04.005. [DOI] [PubMed] [Google Scholar]
- 4.Tello K, Richter MJ, Yogeswaran A, Ghofrani HA, Naeije R, Vanderpool R, et al. Sex differences in right ventricular-pulmonary arterial coupling in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2020;202:1042–1046. doi: 10.1164/rccm.202003-0807LE. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Badagliacca R, Papa S, Matsubara H, Lang IM, Poscia R, Manzi G, et al. The importance of right ventricular evaluation in risk assessment and therapeutic strategies: raising the bar in pulmonary arterial hypertension. Int J Cardiol. 2020;301:183–189. doi: 10.1016/j.ijcard.2019.10.043. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
